POSTN and NETO1 were correlated with androgen receptor expression, a main driver of prostate adenocarcinoma progression.
Finally, five genes were validated in another prostate adenocarcinoma cohort.
Dr. Fuzhong Xue from The Shandong University said, “Prostate cancer is a common malignant tumor and the leading cause of cancer-related mortality in men.”
Prostate adenocarcinoma is the most common type of prostate cancer, whereas other types of prostate cancer are relatively rare.
In this study, the authors used targeted maximum likelihood estimation, a doubly robust method to detect the prognostic genes and estimate both the average and individual causal effects.
When estimating the causal effect of the prognostic gene on the BCR status, controlling too many covariates might result in the poor performance of the estimator.
Thus, they applied the algorithm CovSel to select the minimal conditioning set that was sufficient for unbiased effect estimations of the target gene on the BCR.
Moreover, the causal effects of these genes were estimated for individual therapies.
The Xue Research Team concluded in their Aging-US Research Output, “we used TCGA dataset to identify the potential prognostic genes in PRAD. Using the associations between the immune/stromal scores and the prognosis of PRAD, we revealed a set of genes related to the TME and the BCR of PRAD.
These findings might facilitate the prognosis of PRAD. Based on our study, previously neglected genes could be used as biomarkers for PRAD. Finally, further studies of these genes could provide a more comprehensive understanding of the potential relationship between the prognosis of PRAD and the TME.”
Source: Eurekalert
For all the latest Health News Click Here
For the latest news and updates, follow us on Google News.
Denial of responsibility! NewsBit.us is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
